Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results

被引：0
|
作者：
Buckley, S. [1 ]
Flux, G. [1 ]
Gaze, M. [2 ]
Chittenden, S. [1 ]
Partridge, M. [1 ]
Lancaster, D. [1 ]
Pearson, A. [3 ]
Saran, F. [1 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[2] UCL Hosp, London, England
[3] Inst Canc Res, Sutton, Surrey, England
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2006年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S339 / S339
页数：1
相关论文
共 50 条
  • [1] Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma:: Preliminary results
    Buckley, Susan E.
    Saran, Frank H.
    Gaze, Mark N.
    Chittenden, Sarah
    Partridge, Mike
    Lancaster, Donna
    Pearson, Andrew
    Flux, Glenn D.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (01) : 105 - 112
  • [2] The Role of 131I-MIBG in High-Risk Neuroblastoma Treatment
    Lessig, Megan Kinnear
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2009, 26 (04) : 208 - 216
  • [3] Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma
    Sudbrock, Ferdinand
    Schmidt, Matthias
    Simon, Thorsten
    Eschner, Wolfgang
    Berthold, Frank
    Schicha, Harald
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (07) : 1279 - 1290
  • [4] Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma
    Ferdinand Sudbrock
    Matthias Schmidt
    Thorsten Simon
    Wolfgang Eschner
    Frank Berthold
    Harald Schicha
    European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 : 1279 - 1290
  • [5] Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG
    Sudbrock, F.
    Eschner, W.
    Schmidt, M.
    Simon, T.
    Hero, B.
    Schicha, H.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2006, 45 (06): : 254 - 261
  • [6] Dosimetry during therapy in neuroblastoma paediatric patients treated with 131I-mIBG -: Methodology optimization and preliminary results
    Chiesa, C
    Albertini, F
    Castellani, MR
    Pavesi, R
    Luksch, R
    Bombardieri, E
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S474 - S474
  • [7] Upfront Treatment of High-Risk Neuroblastoma With a Combination of 131I-MIBG and Topotecan
    Kraal, Kathelijne C. J. M.
    Tytgat, Godelieve A. M.
    van Eck-Smit, Berthe L. F.
    Kam, Boen
    Caron, Huib N.
    van Noesel, Max
    PEDIATRIC BLOOD & CANCER, 2015, 62 (11) : 1886 - 1891
  • [8] Effectiveness of high-dose 131I-MIBG as consolidation therapy for the patients with high-risk neuroblastoma
    Inaki, A.
    Kuroda, R.
    Wakabayashi, H.
    Akatani, N.
    Yamase, T.
    Kunita, Y.
    Watanabe, S.
    Hiromasa, T.
    Mori, H.
    Saito, S.
    Ikawa, Y.
    Kayano, D.
    Kinuya, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S279 - S279
  • [9] Preliminary experience in treating high-risk neuroblastoma using tandem high dose dosimetry-guided 131I-MIBG treatment combined with chemotherapy
    Boni, G.
    Mazzarri, S.
    Menconi, M.
    Traino, A. C.
    Borso, E.
    Bernasconi, S.
    Casazza, G.
    Favre, C.
    Volterrani, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S170 - S171
  • [10] Treatment planning for 131I-mIBG Radionuclide therapy of high-risk neuroblastoma based on patient-specific Dosimetry
    Buckley, S.
    Saran, F.
    Gaze, M.
    Hindorf, C.
    Chittenden, S.
    Lancaster, D.
    Pearson, A.
    Flux, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S179 - S179
12345